In this study, we aimed to assess the impact of STING level and the possibility of its activation in two murine cancer cell lines, melanoma (B16-F10) and breast carcinoma (4T1), on the anti-cancer effect of STING-targeting therapy. The gene discussed is STING1; the disease is breast carcinoma.